2007 Speakers

Tony Hunter, Ph.D.Tony Hunter, Ph.D.

  • Professor of Molecular & Cell Biology Member
  • National Academy of Sciences
  • The Salk Institute
  • University of California, San Diego
  • Orrin Ingram Distinguished Lecturer

Signal Transduction in Disease and the Response to DNA Damage

March 1, 2007



Jeffrey Conn, Ph.D.Jeffrey Conn, Ph.D.

  • Professor of Pharmacology and Director of the Vanderbilt Institute for Chemical Biology Program in Drug Discovery, Vanderbilt University School of Medicine

Opportunities and Challenges for Drug Discovery in a Postgenomic World

January 25, 2007

Dr. Conn is Professor of Pharmacology, and founding Director of the Program in Translational Neuropharmacology and the VICB Program in Drug Discovery at Vanderbilt Medical Center. Conn received a Ph.D. degree in Pharmacology from Vanderbilt University in 1986 and pursued postdoctoral studies in the Department of Pharmacology at Yale University. Dr. Conn joined the faculty of the Department of Pharmacology at Emory University in 1988 where he where he rose to the rank of full professor and established himself as a leader in studies of neurotransmitter receptors and their roles in regulating brain function in circuits involved in psychiatric and neurological disorders. In 2000, Dr. Conn moved to Merck and Company to assume the position of senior director and head of the department of neuroscience at Merck’s site in West Point, PA. He also took on the role of Worldwide Head of research in schizophrenia and movement disorders. Dr. Conn moved to Vanderbilt University in 2003 to start a new Program in Drug Discovery, with a primary mission of facilitating translation of recent advances in basic science to novel therapeutics. Since coming to Vanderbilt, Dr. Conn has established a new Program in Drug Discovery. The primary mission of the Program is to facilitate the application of chemical and other technologies to answer fundamental questions in the biological sciences that may ultimately lead to the development of noveltherapeutic strategies. his leadership has been instrumental in landing the appropriate recruits and directing investments in critical technology to establish Vanderbilt as a leader in Drug Discovery efforts. Dr. Conn is Editor in Chief of Molecular Pharmacology, Regional Editor (North America) of Current Neuropharmacology and serves on the editorial boards of six other international journals. Dr. Conn serves on the Scientific Advisory Boards of Addex Pharmaceuticals, Cephalon inc., astrazeneca usa, roche pharmaceuticals, forrest pharmaceuticals, precient Neuropharma, Michael J. Fox Foundation, and the Dystonia Medical Research Foundation. He is the Chair Elect of the Neuropharmacology Division of the American Society for Pharmacology and Experimental Therapeutics (ASPET). He has received numerous awards and honors, including the NARSAD Essel Investigator Distinguished Investigator Award, the Pharmacia-ASPET award in Experimental Therapeutics, the ASPET Astellas Award in Translational Pharmacology, and was named as an ISI Most-Cited Scientists in Pharmacology & Toxicology. He serves on several national and international committees, including international Union of Pharmacology (IUPHAR) subcommittee on receptor nomenclature, Executive Committee, Neuropharmacology Division of ASPET, the ASPET Publications Board of Trust, and is an Expert Consultant, Compound Selection Committee, Treatment Units for Research on Neurocognition and Schizophrenia. Dr. Conn’s current research is focused on development of novel treatment strategies for schizophrenia, Parkinson’s disease, and other brain disorders.



Antonis K. Hatzopoulos, Ph.D.Antonis K. Hatzopoulos, Ph.D.

  • Associate Professor of Medicine and Cell & Developmental Biology, Vanderbilt University Medical Center

Stem Cells and Cardiac Regeneration

February 15, 2007



Elaine Fuchs, Ph.D.Elaine Fuchs, Ph.D.

  • Rebecca C. Lancefield Professor, The Rockefeller University
  • Mammalian Cell Biology & Development
  • Howard Hughes Medical Investigator

Stem Cells and Their Lineages in Skin

February 22, 2007



Agnes Fogo, M.D.Agnes Fogo, M.D.

  • Professor of Pathology, Pediatrics, and Medicine, Vanderbilt University Medical Center

Chronic Kidney Disease: Can We Stop the Epidemic?

March 29, 2007



Emil Unanue, M.D.Emil Unanue, M.D.

  • Paul and Ellen Lacy Professor of Pathology, Washington University in St. Louis

Cellular and Biochemical Basis for Recognition of Beta Cell Antigens in Autoimmune Diabetes

April 12, 2007



Harold (Hal) Moses, M.D.Harold (Hal) Moses, M.D.

  • Director Emeritus, Vanderbilt-Ingram Cancer Center
  • Hortense B. Ingram Professor of Molecular Oncology
  • Professor of Cancer Biology, Medicine and Pathology

TGF-beta Regulation of Stromal-Epithelial Interactions in Cancer

April 26, 2007



Robert Coffey, M.D.Robert Coffey, M.D.

  • Ingram Professor of Cancer Research
  • Joe B. Wallace Professor of Medicine
  • Professor of Cell and Developmental Biology

The Naked Truth about TGF-α: Lessons Learned from Polarized Epithelial Cells and their Relevance to GI Neoplasia

May 10, 2007



Richard Lifton, M.D., Ph.D.Richard Lifton, M.D., Ph.D.

  • Sterling Professor of Genetics
  • Professor of Medicine, Molecular Biophysics and Biochemistry, Yale University School of Medicine
  • Member, Howard Hughes Medical Institute

Genetics, Genomics and the Future of Medicine

May 17, 2007



Kathryn M. Edwards, M.D.Kathryn M. Edwards, M.D.

  • Professor of Pediatrics
  • Director, Division of Pediatric Clinical Research

From Jenner to Genome: New Approaches to Vaccinology

June 7, 2007



Frank E Harrell Jr, Ph.D.Frank E Harrell Jr, Ph.D.

  • Professor of Biostatistics, Department Chair, Vanderbilt University School of Medicine

Information Allergy

September 13, 2007



Bengt Samuelsson, M.D.Bengt Samuelsson, M.D.

  • Nobel Laureate in Physiology/Medicine
  • Dean of the Medical Faculty, Karolinska Institutet, 1978 - 1983
  • Rector of Karolinska Institutet, 1983 – 1995, Stockholm, Sweden

From Biochemical Mechanisms to Novel Drug Targets: The 5-Lipoxygenase Pathway

October 11, 2007



Bradley Efron, Ph.D.Bradley Efron, Ph.D.

  • Max H. Stein Professor of Humanities and Sciences
  • Received the US Medal of Science, the nation's highest scientific honor
  • Member National Academy of Science
  • Professor of Statistics, Stanford University

Baseball, Shakespeare, and Modern Statistical Theory

October 25, 2007



Sir Paul Nurse, Ph.D.Sir Paul Nurse, Ph.D.

  • Nobel Laureate in Physiology/Medicine
  • President of The Rockefeller University

Controlling the Cell Cycle

November 12, 2007



Sten Vermund, M.D.Sten Vermund, M.D.

  • Director, Institute for Global Health
  • Professor of Medicine, Vanderbilt University Medical Center
  • Amos Christie Chair in Global Health
  • Professor of Pediatrics, Medicine, Preventive Medicine, Obstetrics & Gynecology
  • Director, Vanderbilt University School of Medicine's Institute for Global Health

Vanderbilt Global Health Research into 2008

November 15, 2007



Brian Kobilka, M.D.Brian Kobilka, M.D.

  • Professor of Medicine and Molecular and Cellular Physiology, Stanford University

Structure and Dynamics of the Human beta 2 Adrenoceptor

December 5, 2007



Richard Hanson, Ph.D.Richard Hanson, Ph.D.

  • Leonard & Jean Skeggs Professor of Biochemistry Department of Biochemistry, University School of Medicine Cleveland, OH

Phosphoenolpyruvate Carboxykinase: The Joy Of Thinking Outside The Box

December 13, 2007